NDAINTRAVENOUSSOLUTION
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
FLUORODOPA F18 (fluorodopa f18) by Medica Corp is 12. First approved in 2019.
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLUORODOPA F18 is a positron emission tomography (PET) imaging agent that uses fluorine-18 labeled dopamine to visualize dopaminergic nerve terminal function in the brain. After intravenous administration, it is decarboxylated to fluorodopamine and accumulated in the striatum, enabling detection of dopamine system integrity. This diagnostic tool is used to assess neurodegenerative conditions affecting dopaminergic pathways.
Peak
Product is at peak maturity with moderate competitive pressure (30/100); team composition and hiring activity are limited, suggesting a stable, smaller commercial organization around this diagnostic asset.
Mechanism of Action
12.1 Mechanism of Action In dopaminergic nerve terminals in the brain, Fluorodopa (FDOPA) F 18 is decarboxylated by amino acid decarboxylase to Fluorodopamine (FDA) F 18 and stored in presynaptic vesicles in the brain. The accumulation of F 18 FDA in the striatum is visually detected in the PET…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on FLUORODOPA F18 at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.